Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease

Bibliography

• KOVANEN PE, LEONARD WJ: Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. (2004) 202:67-83.
   PubMed Web of Science ®Google Scholar
• SWAIN SL: Lymphokines and the immune response: the central role of interleukin-2. Curr. Opin. Immunol. (1991) 3(3):304-310.
   PubMed Web of Science ®Google Scholar
• PAUL WE, SEDER RA: Lymphocyte responses and cytokines. Cell (1994) 76(2):241-251.
   PubMed Web of Science ®Google Scholar
• SETOGUCHI R, HORI S, TAKAHASHI T, SAKAGUCHI S: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. (2005) 201(5):723-735.
   PubMed Web of Science ®Google Scholar
• GRANUCCI F, ZANONI I, FEAU S, CAPUANO G, RICCIARDI-CASTAGNOLI P: The regulatory role of dendritic cells in the immune response. Int. Arch. Allergy Immunol. (2004) 134(3):179-185.
   PubMed Web of Science ®Google Scholar
• MINAMI Y, KONO T, MIYAZAKI T, TANIGUCHI T: The IL-2 receptor complex: its structure, function, and target genes. Annu. Rev. Immunol. (1993) 11:245-268.
   PubMed Web of Science ®Google Scholar
• MORGAN DA, RUSCETTI FW, GALLO R: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 193(4257):1007-1008.
   PubMed Web of Science ®Google Scholar
• SMITH KA: Interleukin-2: inception, impact, and implications. Science (1988) 240(4856):1169-1176.
   PubMed Web of Science ®Google Scholar
• MULE JJ, SHU S, SCHWARZ SL, ROSENBERG SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 225(4669):1487-1489.
   PubMed Web of Science ®Google Scholar
• SADLACK B, MERZ H, SCHORLE H et al.: Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell (1993) 75(2):253-261.
   PubMed Web of Science ®Google Scholar
• WILLERFORD DM, CHEN J, FERRY JA et al.: Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity (1995) 3(4):521-530.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, KUNDIG TM, FURLONGER C et al.: Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science (1995) 268(5216):1472-1476.
   PubMed Web of Science ®Google Scholar
• SAKAGUCHI S, SETOGUCHI R, YAGI H, NOMURA T: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease. Curr. Top. Microbiol. Immunol. (2006) 305:51-66.
   PubMed Web of Science ®Google Scholar
• SHEVACH EM, MCHUGH RS, PICCIRILLO CA, THORNTON AM: Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol. Rev. (2001) 182:58-67.
   PubMed Web of Science ®Google Scholar
• MALEK TR, BAYER AL: Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. (2004) 4(9):665-674.
   PubMed Web of Science ®Google Scholar
• FONTENOT JD, RASMUSSEN JP, GAVIN MA, RUDENSKY AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. (2005) 6(11):1142-1151.
   PubMed Web of Science ®Google Scholar
• ANTONY PA, PAULOS CM, AHMADZADEH M et al.: Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J. Immunol. (2006) 176(9):5255-5266.
   PubMed Web of Science ®Google Scholar
• BLATTMAN JN, GRAYSON JM, WHERRY EJ et al.: Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. (2003) 9(5):540-547.
   PubMed Web of Science ®Google Scholar
• D’SOUZA WN, SCHLUNS KS, MASOPUST D, LEFRANCOIS L: Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses. J. Immunol. (2002) 168(11):5566-5572.
   PubMed Web of Science ®Google Scholar
• WILLIAMS MA, TYZNIK AJ, BEVAN MJ: Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature (2006) 441(7095):890-893.
   PubMed Web of Science ®Google Scholar
• ANTONY PA, RESTIFO NP: CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. (2005) 28(2):120-128.
   PubMed Web of Science ®Google Scholar
• BOYMAN O, KOVAR M, RUBINSTEIN MP, SURH CD, SPRENT J: Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science (2006) 311(5769):1924-1927.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, WHITE DE, STEINBERG SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. (1998) 228(3):307-319.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, LOTZE MT, DUTCHER JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. (1999) 17(7):2105-2116.
   PubMed Web of Science ®Google Scholar
• OGNIBENE FP, ROSENBERG SA, LOTZE M et al.: Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest (1988) 94(4):750-754.
   PubMed Web of Science ®Google Scholar
• SCHWARTZENTRUBER DJ: Guidelines for the safe administration of high-dose interleukin-2. J. Immunother. (2001) 24(4):287-293.
   PubMed Web of Science ®Google Scholar
• LENTSCH AB, EDWARDS MJ, MILLERFN: Interleukin-2 induces increased platelet-endothelium interactions: a potential mechanism of toxicity. J. Lab. Clin. Med. (1996) 128(1):75-82.
   PubMedGoogle Scholar
• LENTSCH AB, MILLER FN, EDWARDS MJ: Interleukin-2-induced hepatic injury involves temporal patterns of cell adhesion in the microcirculation. Am. J. Physiol. (1997) 272(4 Pt 1):G727-G731.
   PubMed Web of Science ®Google Scholar
• ROSENSTEIN M, ETTINGHAUSEN SE, ROSENBERG SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol. (1986) 137(5):1735-1742.
   PubMed Web of Science ®Google Scholar
• GATELY MK, ANDERSON TD, HAYES TJ: Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J. Immunol. (1988) 141(1):189-200.
   PubMed Web of Science ®Google Scholar
• ANDERSON TD, HAYES TJ, GATELY MK et al.: Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion. Lab. Invest. (1988) 59(5):598-612.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT DF, ATKINS MB: Application of IL-2 and other cytokines in renal cancer. Expert Opin. Biol. Ther. (2004) 4(4):455-468.
   PubMed Web of Science ®Google Scholar
• YANG JC, SHERRY RM, STEINBERG SM et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21(16):3127-3132.
   PubMed Web of Science ®Google Scholar
• BUTLER LD, MOHLER KM, LAYMAN NK et al.: Interleukin-2 induced systemic toxicity: induction of mediators and immunopharmacologic intervention. Immunopharmacol. Immunotoxicol. (1989) 11(2-3):445-487.
   PubMed Web of Science ®Google Scholar
• PEACE DJ, CHEEVER MA: Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J. Exp. Med. (1989) 169(1):161-173.
   PubMed Web of Science ®Google Scholar
• ASSIER E, JULLIEN V, LEFORT J et al.: NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J. Immunol. (2004) 172(12):7661-7668.
   PubMed Web of Science ®Google Scholar
• FRAKER DL, LANGSTEIN HN, NORTON JA: Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J. Exp. Med. (1989) 170(3):1015-1020.
   PubMed Web of Science ®Google Scholar
• EDWARDS MJ, HENIFORD BT, KLAR EA, DOAK KW, MILLER FN: Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy. J. Clin. Invest. (1992) 90(2):637-641.
   PubMed Web of Science ®Google Scholar
• FAIRMAN RP, GLAUSER FL, MERCHANT RE, BECHARD D, FOWLER AA: Increase of rat pulmonary microvascular permeability to albumin by recombinant interleukin-2. Cancer Res. (1987) 47(13):3528-3532.
   PubMed Web of Science ®Google Scholar
• BALUNA R, RIZO J, GORDON BE, GHETIE V, VITETTA ES: Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. USA (1999) 96(7):3957-3962.
   PubMed Web of Science ®Google Scholar
• LENARDO MJ: Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature (1991) 353(6347):858-861.
   PubMed Web of Science ®Google Scholar
• VAN PARIJS L, ABBAS AK: Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science (1998) 280(5361):243-248.
   PubMed Web of Science ®Google Scholar
• ANTONY PA, PICCIRILLO CA, AKPINARLI A et al.: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. (2005) 174(5):2591-2601.
   PubMed Web of Science ®Google Scholar
• SCHIMPL A, BERBERICH I, KNEITZ B et al.: IL-2 and autoimmune disease. Cytokine Growth Factor Rev. (2002) 13(4-5):369-378.
   PubMed Web of Science ®Google Scholar
• REFAELI Y, VAN PARIJS L, LONDON CA, TSCHOPP J, ABBAS AK: Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity (1998) 8(5):615-623.
   PubMed Web of Science ®Google Scholar
• ZHANG H, CHUA KS, GUIMOND M et al.: Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat. Med. (2005) 11(11):1238-1243.
   Web of Science ®Google Scholar
• AHMADZADEH M, ROSENBERG SA: IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2006) 107(6):2409-2414.
   PubMed Web of Science ®Google Scholar
• WANG HY, LEE DA, PENG G et al.: Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 20(1):107-118.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA: The IL-2/IL-15 receptor systems: targets for immunotherapy. J. Clin. Immunol. (2002) 22(2):51-56.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850-854.
   PubMed Web of Science ®Google Scholar
• DONOHUE JH, ROSENBERG SA: The fate of interleukin-2 after in vivo administration. J. Immunol. (1983) 130(5):2203-2208.
   PubMed Web of Science ®Google Scholar
• OHNISHI H, LIN KM, CHU TM: Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. Cancer Res. (1990) 50(4):1107-1112.
   PubMed Web of Science ®Google Scholar
• ANDERSON PM, KATSANIS E, SENCER SF et al.: Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J. Immunother. (1992) 12(1):19-31.
   Google Scholar
• JOHNSTON D, REYNOLDS SR, BYSTRYN JC: Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice. Cancer Immunol. Immunother. (2006) 55(4):412-419.
   PubMed Web of Science ®Google Scholar
• YAO Z, DAI W, PERRY J, BRECHBIEL MW, SUNG C: Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol. Immunother. (2004) 53(5):404-410.
   PubMed Web of Science ®Google Scholar
• HARVILL ET, FLEMING JM, MORRISON SL: In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J. Immunol. (1996) 157(7):3165-3170.
   PubMed Web of Science ®Google Scholar
• RUCKERT R, BRANDT K, HOFMANN U, BULFONE-PAUS S, PAUS R: IL-2-IgG2b fusion protein suppresses murine contact hypersensitivity in vivo. J. Invest. Dermatol. (2002) 119(2):370-376.
   PubMed Web of Science ®Google Scholar
• GILLIES SD, REILLY EB, LO KM, REISFELD RA: Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA (1992) 89(4):1428-1432.
   PubMed Web of Science ®Google Scholar
• HU P, MIZOKAMI M, RUOFF G, KHAWLI LA, EPSTEIN AL: Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood (2003) 101(12):4853-4861.
   PubMed Web of Science ®Google Scholar
• SHANAFELT AB, LIN Y, SHANAFELT MC et al.: A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat. Biotechnol. (2000) 18(11):1197-1202.
   Google Scholar
• LENTSCH AB, NAKAGAWA K, YOSHIDOME H et al.: Distinct biological activities of recombinant forms of human interleukin-2 in vivo. Cancer Immunol. Immunother. (1997) 43(6):331-336.
   PubMed Web of Science ®Google Scholar
• SAMLOWSKI WE, PETERSEN R, CUZZOCREA S et al.: A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat. Med. (2003) 9(6):750-755.
   PubMed Web of Science ®Google Scholar
• HORNYAK SC, ORENTAS DM, KARAVODIN LM, GEHLSEN KR: Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice. Vascul. Pharmacol. (2005) 42(4):187-193.
   PubMed Web of Science ®Google Scholar
• ACRES B, GANTZER M, REMY C et al.: Fusokine interleukin-2/interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicity. Cancer Res. (2005) 65(20):9536-9546.
   PubMed Web of Science ®Google Scholar
• KLEIN B, BRAILLY H: Cytokine-binding proteins: stimulating antagonists. Immunol. Today (1995) 16(5):216-220.
   PubMedGoogle Scholar
• SATO J, HAMAGUCHI N, DOKEN K et al.: Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy (1993) 6(3):225-231.
   PubMedGoogle Scholar
• COURTNEY LP, PHELPS JL, KARAVODIN LM: An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacology (1994) 28(3):223-232.
   PubMed Web of Science ®Google Scholar
• KAMIMURA D, SAWA Y, SATO M et al.: IL-2 In vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J. Immunol. (2006) 177(1):306-314.
   PubMed Web of Science ®Google Scholar
• FINKELMAN FD, MADDEN KB, MORRIS SC et al.: Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol. (1993) 151(3):1235-1244.
   PubMed Web of Science ®Google Scholar
• JONES AT, ZILTENER HJ: Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies. Blood (1993) 82(4):1133-1141.
   PubMed Web of Science ®Google Scholar
• KU CC, MURAKAMI M, SAKAMOTO A, KAPPLER J, MARRACK P: Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science (2000) 288(5466):675-678.
   PubMed Web of Science ®Google Scholar
• SIEGEL JP, PURI RK: Interleukin-2 toxicity. J. Clin. Oncol. (1991) 9(4):694-704.
   PubMed Web of Science ®Google Scholar